Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets

SIMPLE SUMMARY: Immune checkpoint therapies have significantly improved the survival of patients with metastatic melanoma, however approximately 50% of patients exhibit no response. Understanding the underlying clinical, pathologic and genetic factors associated with failed response to immunotherapi...

Descripción completa

Detalles Bibliográficos
Autores principales: Gide, Tuba N., Pires da Silva, Inês, Quek, Camelia, Ferguson, Peter M., Batten, Marcel, Shang, Ping, Ahmed, Tasnia, Menzies, Alexander M., Carlino, Matteo S., Saw, Robyn P. M., Thompson, John F., Scolyer, Richard A., Long, Georgina V., Wilmott, James S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267740/
https://www.ncbi.nlm.nih.gov/pubmed/34202352
http://dx.doi.org/10.3390/cancers13133186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8267740/
https://www.ncbi.nlm.nih.gov/pubmed/34202352
http://dx.doi.org/10.3390/cancers13133186

Ejemplares similares